Top

Reactions Weekly

Published in:

01-01-2023 | Melanoma | Case report

Antineoplastics/methylprednisolone/tocilizumab

Cytokine release syndrome and no improvement: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Menakuru SR, et al. Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept. Case Reports in Oncology 15: 648-653, No. 2, 27 Jun 2022. Available from: URL: http://doi.org/10.1159/000525173

Title: Antineoplastics/methylprednisolone/tocilizumab
Cytokine release syndrome and no improvement: case report
Publication date: 01-01-2023
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Tocilizumab
Cytokines
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-31475-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antineoplastics/methylprednisolone/tocilizumab

Cytokine release syndrome and no improvement: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Antipsychotics

Bortezomib

Serious AEs more likely after mifepristone/misoprostol-induced abortion

Lorazepam

Antineoplastics

Olanzapine